Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 1996

View Archived Issues

Analgesic and antiinflammatory agents superior to capsaicin

NPC-18521, a high-affinity bradykinin B2 receptor antagonist from Scios

New introductions for Faulding's sustained-release morphine product

FDA approves two pain products from Mallinckrodt

BTG licenses analgesic combination to Forest

Xoma/Genentech to commence clinical trials with humanized monoclonal antibody

Ornithine decarboxylase inhibitors for dermatology

ProCyte cleared for clinical trials with wound-healing product

ProCyte issued patents covering hair loss applications

Allergen describes compounds with retinoid-like activity

Interferon gamma-1b enters pivotal trials for atopic dermatitis

Japanese companies report cephems

Carbapenems reported by Merck & Co.

Merck & Co. describes antibiotics active against resistant staphylococci

New antibiotics from Zeneca

Bayer discloses antibacterial agents

Thalidomide effective in chronic erythema multiforme

Virus susceptibility gene finally cloned

HIV protease inhibitor under evaluation at Pharmacia & Upjohn

Antisense anti-HIV agent heading for clinical trials

New AIDS vaccine from the MRC

Another approval for DaunoXome

Grant for potential AIDS preventive/contraceptive from Polydex

Anti-HIV activity reported for Onconase

Women with AIDS-related wasting syndrome to receive testosterone skin patch

Higher doses recommended for Protovir study

CollaGenex and Istituto Gentili collaboration

Interferon production enhancer discovered by Japanese researchers

Abbott describes immunosuppressants

Russian launch for GMDP

VZIG clinical studies progress in post-herpetic neuralgia

Abbott evaluating clitocine analogues

Kosan receives funds for drug design

Generic product from Barr Laboratories cleared by FDA

alpha1-Adrenoceptor antagonist effective in suppressing prostate cancer growth

Additional patent coverage for Maxim anticancer combination

Anticancer benzodiazepines from Genentech

Banyu discloses natural anticancer compounds

Otsuka claims agents for cancer metastasis

Promising results for lung cancer gene therapy

New multidrug resistance modulators

New agents for bone disorders from Banyu

Japanese researchers describe natural lipid-lowering agents

A new CETP inhibitor from Schering-Plough

Retinoid compound from Sparta enters U.S. clinical trials

Oral treatment for periodontitis filed for approval

Assays for the diagnosis of Alzheimer's disease

Agreement reached on tests for hepatitis C virus

MRI contrast agent from Advanced Magnetics cleared for launch

Melatonergic agents from ADIR

Lilly discloses new serotonergic agents

NS-2710 in development for anxiety

Antipsychotic dopaminergic compounds from E. Merck

Lilly's olanzapine deemed approvable

Reversible MAO inhibitors from Hoechst Marion Roussel

NS-2389: a potential new antidepressant

Ontogen and Boehringer Ingelheim sign research agreement

Renewed collaboration for Ribozyme and Pharmacia Biotech

Molecular Simulations and Procept enter research collaboration

ImmunoTherapeutics obtains option for drug delivery technology

Cellegy issued patent covering novel drug delivery system

Memtec and Gelman Sciences sign merger agreement

Baxter to acquire Immuno AG

Zynaxis terminates agreement in principle for sale of chemistry division

MicroCarb name change

ICN to acquire Hungarian pharmaceutical company

Xenova forms new U.S. subsidiary

Mechanism-based enzyme inhibitor may serve as a lead for new anticonvulsants

Fosphenytoin launch imminent

Tiagabine clinical data reported at congress this week

INSERM and Bioprojet describe a new histamine H3 receptor antagonist

Potential new treatment for Alzheimer's disease disclosed by SIBIA Neurosciences

New adenosine A3 receptor antagonist reported at ACS

NeuroSearch compound for the treatment of brain damage

Another NeuroSearch compound for nerve degeneration

Clearance for Schering-Plough's extended-release Claritin-D

Bock Pharmacal introduces antihistamine-free cough syrup

SmithKline Beecham stresses dual PDE IV and TNF production inhibitors

Orally active dual NK1/NK2 antagonist from Merck & Co.

Fujisawa discloses vasopressin antagonists

alpha1-Adrenoceptor blockers with advantages over prazosin

New angiotensin II antagonists from Kotobuki

Zambon selects a dopaminergic compound for evaluation in cardiovascular/renal disorders

CGS-28106 for hypertension and congestive heart failure

Generic nadolol approved

Clinical trials to begin on laser for transmyocardial revascularization

cGMP PDE inhibitors from Taisho

Genentech claims CHF for heart failure and neurological disorders

E. Merck describes cardioactive agents

Arginine analogues for shock

Thalidomide derivatives as leads for septic shock therapy

Hisamitsu describes platelet aggregation inhibitors

Bayer's new cGMP PDE inhibitors

Roche and Genentech prepare prodrugs of fibrinogen antagonist

Monoclonal antibody for thrombotic disorders from Teijin

Genetics Institute's recombinant factor IX submitted for approval

5alpha-Reductase inhibitors for BPH

Potential BPH therapy from Glaxo Wellcome

Finasteride clinical utility continues to be debated

Urethral insert approved for female stress incontinence

Potential use for YM-934 in bladder hypersensitivity

Darifenacin for urge incontinence

Cimetidine for treatment of interstitial cystitis

LeukoSite awarded SBIR grant for inflammatory bowel disease research

Trypsin inhibitors for pancreatitis

Terumo pursues treatments for diabetes and complications

Clinical results for Cortecs' oral insulin formulation

Location of gene linked to type 2 diabetes discovered

Novo Nordisk licenses Scios' insulinotropin

AGE-specific monoclonal antibody from Alteon

Bio-Technology General to seek approval for sublingual testosterone

Joint venture to develop treatment for male impotence

Safe and effective treatment of erectile dysfunction with sildenafil

Moxisylyte to treat erectile dysfunction

U.S. approval for Serono infertility product

Meiji Seika discloses natural progesterone antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...